Processing technology firm Pall Life Sciences has introduced a 200L version of its Allegro single-use mixer for biopharmaceutical manufacturing.
Pall's Allegro range comprises 2D and 3D biocontainers linked to Novasip filter capsules and Mustang membrane chromatography systems. The units also include bags for collection and transport of process solutions, product intermediates and cell-culture media.
This latest addition to the portfolio, which was launched in 2009, is designed to improve the efficiency of critical mixing processes throughout the drug production cycle for a wide range of liquid-liquid and solid-liquid mixing applications.
Ken Frank, president of Pall's Biopharmaceutical Division, said that: "Reduced drug development timelines, smaller batch sizes, increased safety requirements and more stringent validation guidelines are all driving the demand for single-use solutions in drug production.
Adding a high-performance, single-use mixing solution to Pall's Allegro single-use platform that is particularly well suited for critical applications gives biopharmaceutical manufacturers an important new tool to improve process efficiencies and help speed product to market.
Pall's investment in its bioprocessing offering is unsurprising given that the division has been a key driver for it in the current fiscal year.
For example, for the three months ended April 30 Palls biopharmaceutical business contributed revenue of $197m (136m), up just over 21 per cent from that recorded in the comparable period in the previous fiscal year.
This continues the pattern seen in the prior quarter, where revenue from bioprocessing technologies increased 22 per cent to $179.5m.
According to a prediction by Zacks Investment Research the demand for single use solutions is on rise due to the decline in timelines for drug development, increased safety requirements and more stringent validation guidelines.